Back to Search
GLENN BUBLEY, MD
MD
Hematology & Oncology Physician
NPI: 1881614485IndividualAccepts Medicare
Specialties, Licenses & Credentials
Hematology & Oncology PhysicianPrimary
Internal Medicine — Hematology & Oncology
Code: 207RH0003X
46555(MA)
Education
MICHIGAN STATE UNIVERSITY COLLEGE OF HUMAN MEDICINE
Class of 1977
Research & Publications (20)
Serum levels of insulin-like growth factor-1 and insulin-like growth factor-1 binding proteins after radical prostatectomy.
PMID 12394769·J Urol·2002
8-other
Detection of TMPRSS2-ERG fusion gene expression in prostate cancer specimens by a novel assay using branched DNA.
PMID 19647299·Urology·2009
8-other
A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.
PMID 18399827·BJU Int·2008
3-trial
Hypoxia-inducible factor-2alpha: effect on radiation sensitivity and differential regulation by an mTOR inhibitor.
PMID 18394010·BJU Int·2008
8-other
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
PMID 18309951·J Clin Oncol·2008
6-review
A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.
PMID 18085595·Cancer·2008
3-trial
Hypoxia-inducible factor-1alpha (HIF-1alpha) gene polymorphisms, circulating insulin-like growth factor binding protein (IGFBP)-3 levels and prostate cancer.
PMID 17624927·Prostate·2007
8-other
Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.
PMID 17509304·J Urol·2007
3-trial
A phase I trial of docetaxel/estramustine/imatinib in patients with hormone-refractory prostate cancer.
PMID 17645829·Clin Genitourin Cancer·2007
3-trial
Combining an mTOR antagonist and receptor tyrosine kinase inhibitors for the treatment of prostate cancer.
PMID 17218776·Cancer Biol Ther·2007
8-other
The effect of androgen deprivation therapy on fasting serum lipid and glucose parameters.
PMID 16813881·J Urol·2006
8-other
Androgen receptor remains critical for cell-cycle progression in androgen-independent CWR22 prostate cancer cells.
PMID 16877366·Am J Pathol·2006
7-preclinical
Microwave expedited synthesis of 5-aminocamptothecin analogs: Inhibitors of hypoxia inducible factor HIF-1alpha.
PMID 16971123·Bioorg Med Chem Lett·2006
8-other
Androgen receptor phosphorylation and stabilization in prostate cancer by cyclin-dependent kinase 1.
PMID 17043241·Proc Natl Acad Sci U S A·2006
8-other
Prostate cancer in a transgender woman 41 years after initiation of feminization.
PMID 17105793·JAMA·2006
5-case
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 330 BROOKLINE AVE, RM1026 BETH ISRAEL HOSPITAL
BOSTON, MA 02215 - Phone
- (617) 667-5288
Quick Facts
- NPI
- 1881614485
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 49
- Publications
- 20
Are you this provider?
Claim Your Profile